- Home
- CNQ vs SNY Comparison
CNQ vs SNY Comparison
Compare CNQ & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CNQ | SNY |
|---|---|---|
| Founded | 1973 | 1994 |
| Country | Canada | France |
| Employees | N/A | 74846 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 88.3B | 116.8B |
| IPO Year | 2001 | N/A |
Fundamental Metrics
Financial Performance| Metric | CNQ | SNY |
|---|---|---|
| Price | $48.41 | $43.50 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | $57.00 | ★ $61.50 |
| AVG Volume (30 Days) | ★ 9.1M | 3.7M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | 3.50% | ★ 3.67% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $3.01 |
| Revenue Next Year | $2.64 | $5.80 |
| P/E Ratio | $18.33 | ★ $6.14 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $24.65 | $43.49 |
| 52 Week High | $48.87 | $59.17 |
Technical Indicators
Market Signals| Indicator | CNQ | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 82.82 | 31.35 |
| Support Level | $30.44 | N/A |
| Resistance Level | N/A | $48.97 |
| Average True Range (ATR) | 1.25 | 0.69 |
| MACD | 0.23 | -0.35 |
| Stochastic Oscillator | 93.46 | 2.66 |
Price Performance
Historical ComparisonAbout CNQ Canadian Natural Resources Limited
Canadian Natural Resources is the largest producer of oil and the second-largest producer of natural gas in Canada. It is principally involved in extracting heavy oils, natural gas, and bitumen through its drilling and mining operations. Bitumen from mining operations is upgraded into synthetic crude oil. Commodities produced are primarily exported to the US via pipeline. The company also has smaller offshore production operations in the North Sea and Africa.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.